A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Patients from a tertiary endocrine center at a University Hospital in Munich, Germany, were tested using Metyrapone (Metopirone®, HRA Pharma, France), administered at a dose of 40 mg/kg bodyweight at 8 a.m. Levels of ACTH were determined at 0, 60, 120, 180, and 240 minutes. Patients were categorized according to their need of glucocorticoid substitution at the end of follow-up. The study was approved by the local Ethics Committee with a limitation to 25 patients.doi:10.1530/endoabs.41.gp168 fatcat:5d7xo7hbfrghfjn363ssshsoy4